Broder; Cancer Act’s Special Authorities Don’t Give Director Immunity For NIH, HHS
In Brief: House, Senate Enact FY ’92 Budget Bills For NCI That Differ By $200 Million; Senate’s Is Higher
Bypass Budget Is Realistic, Defensible Plan, Broder Says
Broder On FDA: Don’t Blame Them For Doing Their Jobs (They Have To Work At Parklawn)
Tipping Resigned Forom ACS Following Volunteer Discontent
NSABP Sees Groups To Join Breast Cancer Prevention Trial
Trending Stories
- On Day 2 as director of NYU Perlmutter, Anirban Maitra talks about the advantages of running a matrix cancer center
- Spending bill passed by the House gives NIH $415M raise, NCI gets $128M
Legislation caps proportion of NIH grants to receive multiyear funding; indirect costs remain untouched - Letai: NCAB’s ad hoc working group plays major role in advising NCI on extramural research
The group replaced the NCI Board of Scientific Advisors - Supportive cancer care is the smart investment our leaders in Washington can’t afford to ignore
- Mail-out colorectal cancer screening programs extend, rather than replace, clinical care
- After a brief government shutdown, FY26 funding bill is signed into law
NIH gets $415M raise, NCI gets $128M more, CDMRP funding largely restored









